

Medicine summary - trifluoperazine (to end January 2009)

			Case Group	Death Outcomes	Sole
Case Count			275	5	129
Reaction Count	Blood and lymphatic system disorders	Anaemia	4	0	1
		Anaemia macrocytic	1	0	0
		Thrombocythaemia	1	0	0
		Thrombocytopenia	4	0	3
		Splenomegaly	2	0	1
		Leukocytosis	4	0	0
		Leukopenia	1	0	0
		Agranulocytosis	4	1	0
		Neutropenia	4	0	0
		Blood and lymphatic system disorders	25	1	5
	Cardiac disorders	Tachycardia	6	0	2
		Cardiac disorder	1	1	0
		Palpitations	1	0	0
		Cardiac disorders	8	1	2
	Congenital, familial and genetic disorders	Ventricular septal defect	1	0	1
		Gastrointestinal malformation	1	0	0
		Congenital hand malformation	1	0	1
		Congenital, familial and genetic disorders	3	0	2
	Ear and labyrinth disorders	Ear pain	1	0	1
		Hyperacusis	2	0	2
		Tinnitus	2	0	2
		Vertigo	1	0	1
		Ear and labyrinth disorders	6	0	6
	Endocrine disorders	Diabetes insipidus	1	0	0
		Endocrine disorders	1	0	0
Eye disorders	Conjunctivitis	1	0	0	
	Oculogyric crisis	6	0	6	
	Mydriasis	1	0	1	
	Photophobia	1	0	0	
	Accommodation disorder	1	0	1	
	Diplopia	1	0	1	
	Visual impairment	7	0	4	
	Eye disorders	18	0	13	
Gastrointestinal disorders	Tooth discolouration	1	0	1	
	Haematemesis	1	1	0	
	Diarrhoea	1	0	0	
	Constipation	6	0	2	
	Abdominal pain	4	0	3	
	Dysphagia	3	0	3	
	Nausea	6	0	5	
	Vomiting	5	0	4	

Medicine summary - trifluoperazine (to end January 2009)

		Case Group	Death Outcomes	Sole	
Reaction Count	Gastrointestinal disorders	Oesophagitis ulcerative	1	0	1
		Mouth ulceration	3	0	1
		Ascites	1	1	0
		Dry mouth	3	0	1
		Salivary hypersecretion	2	0	1
		Glossitis	1	0	0
		Tongue oedema	1	0	1
		Gastrointestinal disorders	39	2	23
	General disorders and administration site conditions	Hyperthermia malignant	1	0	0
		Hypothermia	2	0	2
		Pyrexia	9	0	1
		Sudden death	1	1	0
		Asthenia	2	0	1
		Fatigue	3	0	1
		Gait disturbance	4	0	3
		Granuloma	1	0	1
		Face oedema	3	0	1
		Gravitational oedema	1	0	0
		Oedema	2	0	1
		Oedema peripheral	2	0	0
		Chest pain	1	0	0
		Pain	3	0	3
		Chills	3	0	0
		Drug ineffective	3	0	1
		General disorders and administration site conditions	41	1	15
	Hepatobiliary disorders	Hepatitis cholestatic	3	0	1
		Hyperbilirubinaemia	1	0	1
		Jaundice	8	1	1
		Hepatic function abnormal	4	0	2
		Hepatic failure	1	1	0
		Hepatic cirrhosis	1	1	0
		Hepatomegaly	4	0	0
		Hepatic steatosis	1	0	0
		Hepatitis	3	0	1
		Hepatocellular injury	1	0	0
		Hepatobiliary disorders	27	3	6
	Infections and infestations	Sepsis	2	1	0
		Rhinitis	1	0	1
		Sinusitis	1	0	1
		Infections and infestations	4	1	2
	Injury, poisoning and procedural complications	Fall	1	0	0

Medicine summary - trifluoperazine (to end January 2009)

			Case Group	Death Outcomes	Sole
Reaction Count	Injury, poisoning and procedural complications	Overdose	2	0	0
		Injury, poisoning and procedural complications	3	0	0
	Investigations	Blood creatine phosphokinase increased	8	0	2
		Blood alkaline phosphatase increased	2	0	1
		Red blood cell sedimentation rate increased	2	0	1
		Transaminases increased	1	0	0
		Body temperature increased	1	0	1
		Weight decreased	4	0	1
		Weight increased	3	0	2
		Investigations	21	0	8
		Metabolism and nutrition disorders	Anorexia	3	1
	Hypocalcaemia		1	0	0
	Tetany		1	0	1
	Polydipsia		1	0	1
	Hypokalaemia		3	0	0
	Hyponatraemia		7	0	2
	Dehydration		3	0	1
	Hyperglycaemia		1	0	0
	Hypercholesterolaemia		1	0	0
	Hypertriglyceridaemia		1	0	0
	Metabolism and nutrition disorders		22	1	7
	Musculoskeletal and connective tissue disorders	Osteoporosis	1	0	0
		Pathological fracture	1	0	0
		Arthralgia	3	0	1
		Myalgia	4	0	3
		Muscle rigidity	1	0	0
		Torticollis	2	0	2
		Musculoskeletal and connective tissue disorders	12	0	6
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer female	1	0	0
		Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1	0	0
	Nervous system disorders	Cerebral haemorrhage	1	1	0
Encephalopathy		1	1	0	
Toxic encephalopathy		1	0	0	
Headache		7	0	4	
Migraine		1	0	0	
Amnesia		2	0	1	
Disturbance in attention		1	0	0	
Choreoathetosis		3	0	2	
Dyskinesia		11	0	6	
Extrapyramidal disorder		31	0	20	

Medicine summary - trifluoperazine (to end January 2009)

			Case Group	Death Outcomes	Sole		
Reaction Count	Nervous system disorders	Hyperkinesia	18	0	12		
		Movement disorder	1	0	1		
		Tardive dyskinesia	21	0	8		
		Dystonia	20	0	15		
		Opisthotonus	1	0	1		
		Paralysis	1	0	1		
		Paresis	1	0	1		
		Tremor	13	0	7		
		Hyperreflexia	1	0	1		
		Ataxia	5	0	2		
		Consciousness fluctuating	2	0	0		
		Loss of consciousness	1	0	0		
		Somnolence	7	0	2		
		Stupor	1	0	1		
		Syncope	2	0	2		
		Dizziness	3	0	2		
		Meningism	1	0	0		
		Myoclonus	1	0	0		
		Hyperaesthesia	1	0	0		
		Paraesthesia	5	0	3		
		Hypoaesthesia	1	0	1		
		Dysarthria	1	0	0		
		Speech disorder	4	0	3		
		Hypertonia	11	0	6		
		Neuroleptic malignant syndrome	12	1	3		
		Neuropathy peripheral	1	0	0		
		Convulsion	6	0	2		
			Nervous system disorders		201	3	107
		Pregnancy, puerperium and perinatal conditions	Intra-uterine death		1	0	0
			Pregnancy, puerperium and perinatal conditions		1	0	0
		Psychiatric disorders	Agitation		7	0	5
			Anxiety		1	0	0
			Nervousness		1	0	1
			Catatonia		2	0	0
Bruxism			1	0	0		
Confusional state			6	0	0		
Delirium			1	0	0		
Depression			2	0	2		
Depersonalisation			2	0	2		
Hallucination			6	0	2		
Hallucination, visual			1	0	0		

Medicine summary - trifluoperazine (to end January 2009)

			Case Group	Death Outcomes	Sole
Reaction Count	Psychiatric disorders	Thinking abnormal	3	0	2
		Euphoric mood	1	0	0
		Mood swings	1	0	0
		Apathy	1	0	1
		Withdrawal syndrome	3	0	2
		Psychotic disorder	2	0	1
		Libido decreased	1	0	1
		Insomnia	5	0	4
		Nightmare	1	0	1
		Suicide attempt	1	0	0
		Psychiatric disorders	49	0	24
	Renal and urinary disorders	Anuria	1	0	0
		Renal failure acute	1	0	0
		Renal impairment	3	0	0
		Micturition disorder	2	0	0
		Pollakiuria	1	0	1
		Urinary retention	1	0	1
		Haematuria	1	0	0
		Renal and urinary disorders	10	0	2
	Reproductive system and breast disorders	Breast enlargement	1	0	0
		Galactorrhoea	2	0	0
		Amenorrhoea	2	0	1
		Sexual dysfunction	1	0	1
		Reproductive system and breast disorders	6	0	2
	Respiratory, thoracic and mediastinal disorders	Dyspnoea	6	0	3
		Cough	1	0	0
		Productive cough	1	0	0
		Epistaxis	1	0	0
		Respiratory, thoracic and mediastinal disorders	9	0	3
	Skin and subcutaneous tissue disorders	Angioedema	3	0	1
		Urticaria	4	0	1
		Dermatitis bullous	2	0	0
		Toxic epidermal necrolysis	1	0	0
		Skin discolouration	2	0	1
		Dermatitis	1	0	1
		Rash erythematous	2	0	1
		Dermatitis exfoliative	1	0	1
		Photosensitivity reaction	4	0	2
		Pruritus	4	0	1
		Rash	8	0	2
		Rash maculo-papular	7	0	5
		Acne	1	0	1

Medicine summary - trifluoperazine (to end January 2009)

			Case Group	Death Outcomes	Sole	
Reaction Count	Skin and subcutaneous tissue disorders	Alopecia	1	0	0	
		Hyperhidrosis	6	0	3	
		Skin and subcutaneous tissue disorders	47	0	20	
	Surgical and medical procedures	Therapy regimen changed	1	0	0	
		Surgical and medical procedures	1	0	0	
	Vascular disorders	Hypotension	2	0	0	
		Orthostatic hypotension	2	0	1	
		Thrombosis	1	0	0	
		Vein disorder	1	0	1	
		Flushing	1	0	0	
		Pallor	1	0	0	
		Haemorrhage	1	0	0	
		Hypertension	6	0	1	
		Vascular disorders	15	0	3	
		Reaction			570	13